Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review

BackgroundPulmonary sarcomatoid carcinoma (PSC) is a unique subtype of non-small cell lung cancer (NSCLC) with a high degree of malignancy and poor therapeutic effects. With the widespread use of immune checkpoint inhibitors (ICIs) in recent years, few studies have reported that immunotherapy is eff...

Full description

Bibliographic Details
Main Authors: Shugui Wu, Shanlian Wu, Xiaohong Liao, Chaoming Zhou, Feng Qiu, Chen Wang, Wenjuan Zhong
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
pulmonary sarcomatoid carcinoma
pembrolizumab
anlotinib
tumor mutation burden
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274937/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274937/full

Similar Items